← Oncology Approval Tracker

FDA DECISION ·

Rozlytrek oral pellets

entrectinib · Genentech

Accelerated approvalNew formulationTumor-agnostic solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The oral pellet formulation was approved for the same age-expanded NTRK fusion-positive solid tumor indication in adults and children older than one month. The label covers metastatic disease or cases where surgery would likely cause severe morbidity, with progression after treatment or no satisfactory alternative, and excludes known acquired resistance mutations.

LAMPGEN ANALYSIS

Why it matters

The new presentation provides a separate administration option for a population that includes young children.

What research teams should watch

Check the formulation-specific label, weight and how caregivers will prepare and administer the dose.

PRIMARY RECORDS

Sources